These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 9499664

  • 1. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
    [Abstract] [Full Text] [Related]

  • 2. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
    [Abstract] [Full Text] [Related]

  • 3. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 4. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR, Christiansen NP, Frankel SR, Brunetto VL, Mrózek K, Bloomfield CD, Herzig GP.
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [Abstract] [Full Text] [Related]

  • 5. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH, Kantarjian HM, O'Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M.
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [Abstract] [Full Text] [Related]

  • 6. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Mar; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 7. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P, Vítek A, Michalová K, Zemanová Z, Lukásová M.
    Vnitr Lek; 2003 Mar; 49(3):174-80. PubMed ID: 12728590
    [Abstract] [Full Text] [Related]

  • 8. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, Galbusera V, Carrara P, Miglino M, Varaldo R, Ballerini F, Venturino C, Cerri R, Risso M, Balleari E, Carella AM, Sessarego M, Ghio R, Bacigalupo A, Gobbi M.
    J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
    [Abstract] [Full Text] [Related]

  • 9. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [Abstract] [Full Text] [Related]

  • 10. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
    Chen YC, Lin SF, Yao M, Chen TY, Tsao CJ, Chen TP.
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):30-4. PubMed ID: 8916314
    [Abstract] [Full Text] [Related]

  • 11. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN, Fernández-Jurado A, Martino ML, Diéguez JC, Moreno MV, Quesada JA, Polo B, Cañavate M, Amian A, Prados D.
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [Abstract] [Full Text] [Related]

  • 12. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
    Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M.
    Haematologica; 1996 Feb; 81(6):513-20. PubMed ID: 9009438
    [Abstract] [Full Text] [Related]

  • 13. Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis.
    Okamoto T, Kanamaru A, Shimazaki C, Motoji T, Takemoto Y, Takahashi M, Fukushima T, Takeshita A, Kusumoto GS, Kishimoto Y, Yorimitsu S, Tsukuda K, Uike N, Arima N, Ohno R.
    Int J Hematol; 2000 Aug; 72(2):200-5. PubMed ID: 11039669
    [Abstract] [Full Text] [Related]

  • 14. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
    Masaoka T, Ogawa M, Yamada K, Kimura K, Ohhashi Y.
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
    [Abstract] [Full Text] [Related]

  • 15. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z, Cholovitsh M, Elezovitsh I, Vidovitsh A, Radoshevitsh-Radojkovitsh N, Boshkovitsh D, Novak A, Basara N.
    Srp Arh Celok Lek; 1995 Oct; 123(11-12):279-85. PubMed ID: 16296239
    [Abstract] [Full Text] [Related]

  • 16. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M.
    Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
    [Abstract] [Full Text] [Related]

  • 17. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R, Guardia R, Altés A, Sureda A, Brunet S, Sierra J.
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [Abstract] [Full Text] [Related]

  • 18. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S, Paydas S, Disel U, Sahin B.
    Am J Ther; 2006 Mar; 13(5):389-93. PubMed ID: 16988532
    [Abstract] [Full Text] [Related]

  • 19. Standard induction and low dose ara-C treatment in patients over 60 with AML or MDS.
    van Geel BM, Huijgens PC, Ossenkoppele GJ, Wijermans PW, Langenhuijsen MM.
    Neth J Med; 1989 Oct; 35(3-4):128-36. PubMed ID: 2601790
    [Abstract] [Full Text] [Related]

  • 20. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
    Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F.
    Haematologica; 1997 Oct; 82(6):664-7. PubMed ID: 9499665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.